Search research articles
Contact Us
Filters
Showing results (81-90 of 301) with videos related to
Page
of 31
Sort By:
The Journal of Experimental Medicine
|
September 1, 1974
On the relation of products of activated lymphocytes to cell-mediated cytolysis
C S Henney, J Gaffney, B R Bloom
Transplantation
|
February 1, 1982
Display of the neutral glycolipid ganglio-n-tetraosylceramide (asialo GM1) on cells of the natural killer and T lineages
B N Beck, S Gillis, C S Henney
The Journal of Experimental Medicine
|
September 1, 1981
Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells
S Gillis, A E Gillis, C S Henney
Current Medical Research and Opinion
|
January 3, 2008
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury
Leonard Kamen, Herbert R Henney, Jacob D Runyan
The Journal of Clinical Investigation
|
April 1, 1975
Properties of a subpopulation of T cells bearing histamine receptors
M Plaut, L M Lichtenstein, C S Henney
American Journal of Veterinary Research
|
August 1, 1988
Equine neonatal isoerythrolysis: evidence for prevention by maternal antibodies to the Ca blood group antigen
E Bailey, D G Albright, P J Henney
Therapeutics and Clinical Risk Management
|
January 8, 2015
Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
Michele Jara, Matthew F Sidovar, Herbert R Henney
FEBS Letters
|
June 8, 1999
Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89
S Ye, C Whatling, H Watkins, et al.
Pulmonary Pharmacology & Therapeutics
|
July 2, 2002
The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis
P C Glynn, E Henney, I P Hall
Annals of the New York Academy of Sciences
|
August 27, 2014
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Andrew R Blight, Herbert R Henney, Ron Cohen
Page
of 31
Search research articles
Search
Showing results (81-90 of 301) with videos related to
Sort By:
Page
of 31
The Journal of Experimental Medicine
|
September 1, 1974
On the relation of products of activated lymphocytes to cell-mediated cytolysis
C S Henney, J Gaffney, B R Bloom
Transplantation
|
February 1, 1982
Display of the neutral glycolipid ganglio-n-tetraosylceramide (asialo GM1) on cells of the natural killer and T lineages
B N Beck, S Gillis, C S Henney
The Journal of Experimental Medicine
|
September 1, 1981
Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells
S Gillis, A E Gillis, C S Henney
Current Medical Research and Opinion
|
January 3, 2008
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury
Leonard Kamen, Herbert R Henney, Jacob D Runyan
The Journal of Clinical Investigation
|
April 1, 1975
Properties of a subpopulation of T cells bearing histamine receptors
M Plaut, L M Lichtenstein, C S Henney
American Journal of Veterinary Research
|
August 1, 1988
Equine neonatal isoerythrolysis: evidence for prevention by maternal antibodies to the Ca blood group antigen
E Bailey, D G Albright, P J Henney
Therapeutics and Clinical Risk Management
|
January 8, 2015
Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
Michele Jara, Matthew F Sidovar, Herbert R Henney
FEBS Letters
|
June 8, 1999
Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89
S Ye, C Whatling, H Watkins, et al.
Pulmonary Pharmacology & Therapeutics
|
July 2, 2002
The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis
P C Glynn, E Henney, I P Hall
Annals of the New York Academy of Sciences
|
August 27, 2014
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Andrew R Blight, Herbert R Henney, Ron Cohen
Page
of 31